Kaleen N. Hayes

Kaleen N. Hayes

Auto-generated profile, based on publicly available information

Kaleen N. Hayes

Department of Epidemiology Brown University School of Public Health Providence Rhode Island USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
Suzanne M. CadaretteSuzanne M. Cadarette
Suzanne M. Cadarette
MMMalcolm Maclure
Malcolm Maclure
JDJ. A. Chris Delaney
J. A. Chris Delaney
HWHeather J. Whitaker
Heather J. Whitaker
KHKaleen N. Hayes
Kaleen N. Hayes
JHJesper Hallas
Jesper Hallas
Purpose: Consensus is needed on conceptual foundations, terminology and relationships among the various self‐controlled “trigger” study designs that control for time‐invariant confounding factors and target the association between transient exposures (potential triggers) and abrupt outcomes. The International Society for Pharmacoepidemiology (ISPE) funded a working group of ISPE members to develop guidance material for the application and reporting of self‐controlled study designs, similar to Standards of Reporting Observational Epidemiology (STROBE). This first paper focuses on navigation between the types of self‐controlled designs to permit a foundational understanding with guiding principles.Methods: We leveraged a systematic review of applications of these designs, that we term Self‐controlled Crossover Observational PharmacoEpidemiologic (SCOPE) studies. Starting from first principles and using case examples, we reviewed outcome‐anchored (case‐crossover [CCO], case‐time control [CTC], case‐case‐time control [CCTC]) and exposure‐anchored (self‐controlled case‐series [SCCS]) study designs.Results: Key methodological features related to exposure, outcome and time‐related concerns were clarified, and a common language and worksheet to facilitate the design of SCOPE studies is introduced.Conclusions: Consensus on conceptual foundations, terminology and relationships among SCOPE designs will facilitate understanding and critical appraisal of published studies, as well as help in the design, analysis and review of new SCOPE studies. This manuscript is endorsed by ISPE.

Verified
Journal Article
Open access
PDF file
KHKaleen N. Hayes
Kaleen N. Hayes
EWE.M.Winter Winter
E.M.Winter Winter
Suzanne M. CadaretteSuzanne M. Cadarette
Suzanne M. Cadarette
ABAndrea Burden
Andrea Burden
Bisphosphonates are first-line therapy for osteoporosis, with alendronate, risedronate, and zoledronate as the main treatments used globally. After one year of therapy, bisphosphonates are retained in bone for extended periods with extended anti-fracture effects after discontinuation. Due to this continued fracture protection and the potential for rare adverse events associated with long-term use (atypical femoral fractures and osteonecrosis of the jaw), a drug holiday of two to three years is recommended for most patients after long-term bisphosphonate therapy. The recommendation for a drug holiday up to three years is derived primarily from extensions of pivotal trials with alendronate and zoledronate and select surrogate marker studies. However, certain factors may modify the duration of bisphosphonate effects on a drug holiday and warrant consideration when determining an appropriate time off-therapy. In this narrative review, we recall what is currently known about drug holidays and discuss what we believe to be the primary considerations and areas for future research regarding drug holiday duration: total bisphosphonate exposure, type of bisphosphonate used, bone mineral density and falls risk, and patient sex and body weight.

14 July 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
KHKaleen N. Hayes
Kaleen N. Hayes
VGVasily Giannakeas
Vasily Giannakeas
AWAndy Kin On Wong
Andy Kin On Wong
Antiresorptive medications have been explored for treating knee osteoarthritis (OA); however, little data exist on the effects of today's more potent nitrogen‐containing oral bisphosphonates on radiographic disease‐progression in patients with varying disease‐severity, especially those who are not overweight. The primary objective of this cohort study was to determine if the use of bisphosphonates is protective against 2‐year radiographic‐progression of knee OA in Osteoarthritis Initiative (OAI) participants, stratified by baseline radiographic disease‐status. Secondary objectives were to examine effects in non‐overweight participants (body mass index [BMI] < 25 kg/m2) and cumulative bisphosphonate exposure effects. We identified female OAI participants aged ≥50 years and excluded those missing baseline radiograph readings, bisphosphonate use information, or all clinical questionnaire information at baseline. Participants reporting bisphosphonate use (69% alendronate) were propensity‐matched 1:1 to non‐bisphosphonate‐users and followed until first radiographic knee OA‐progression (1‐unit increase in Kellgren and Lawrence [KL] grade) or data were censored (first missed visit or end of 2‐year follow‐up). Discrete‐time logistic regression models estimated hazard‐ratios between bisphosphonate‐users versus non‐users, with an interaction term for baseline KL grade (KL < 2 or KL≥2). We identified 1,977 eligible women (N = 346 bisphosphonate‐users). Propensity‐matched results indicated that bisphosphonate‐users with KL grade < 2 were protected against progression (HRKL < 2 0.53 [95% CI 0.35 to 0.79])), while bisphosphonate use was not associated with radiographic progression in those with KL grade ≥ 2 (HRKL ≥ 2 1.06 [95% CI 0.83 to 1.35]). When restricting analyses to those with BMI < 25 kg/m2, effects were strengthened (HRKL < 2 0.49 [95% CI 0.26 to 0.92]; HRKL ≥ 2 0.69 [95% CI 0.33 to 1.26]). Duration of bisphosphonate use had no effect on progression, though sample size was limited. Bisphosphonate therapy may be protective against radiographic knee OA progression in early‐stage patients, particularly those who are non‐overweight, but less so for those with more advanced disease or more weight‐bearing joint stress.

1 March 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
KHKaleen N. Hayes
Kaleen N. Hayes
KBKevin A. Brown
Kevin A. Brown
ACAngela M. Cheung
Angela M. Cheung
SKSandra A. Kim
Sandra A. Kim
DJDavid N. Juurlink
David N. Juurlink
Suzanne M. CadaretteSuzanne M. Cadarette
Suzanne M. Cadarette
This study analyzed data from patients in Ontario who had taken alendronate and risedronate for at least 3 years and subsequently underwent a drug holiday to compare the effectiveness of these medi... Visual Risedronate Versus Alendronate Risks During Drug Holidays. This study analyzed data from patients in Ontario who had taken alendronate and risedronate for at least 3 years and subse... Background: An osteoporosis drug holiday is recommended for most patients after 3 to 5 years of therapy. Risedronate has a shorter half-life than alendronate, and thus the residual length of fractu...

7 November 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
KHKaleen N. Hayes
Kaleen N. Hayes
TZTingting Zhang
Tingting Zhang
DKDae Hyun Kim
Dae Hyun Kim
LDLori A. Daiello
Lori A. Daiello
YLYoojin Lee
Yoojin Lee
AZAndrew R Zullo
Andrew R Zullo
Background: Dose reduction of direct oral anticoagulant (DOAC) medications is inconsistently applied to older adults with multiple morbidities, potentially due to perceived harms and unknown benefits of standard dosing. Methods and Results: Using 2013 to 2017 US Medicare claims linked to Minimum Data Set records, we conducted a retrospective cohort study. We identified DOAC initiators (apixaban, dabigatran, rivaroxaban) aged ≥65 years with nonvalvular atrial fibrillation residing in a nursing home. We estimated inverse‐probability of treatment weights for DOAC dose using propensity scores. We examined safety (hospitalization for major bleeding) and effectiveness outcomes (all‐cause mortality, thrombosis [myocardial infarction, stroke, systemic embolism, venous thromboembolism]). We estimated hazard ratios (HRs) and 95% CIs using cause‐specific hazard‐regression models. Of 21 878 DOAC initiators, 48% received reduced dosing. The mean age of residents was 82.0 years, 66% were female, and 31% had moderate/severe cognitive impairment. After estimating inverse‐probability of treatment weights, standard dosing was associated with a higher rate of bleeding (HR, 1.18 [95% CI, 1.03–1.37]; 9.4 versus 8.0 events per 100 person‐years). Standard‐dose therapy was associated with the highest rates of bleeding among those aged >80 years (9.1 versus 6.7 events per 100 person‐years) and with a body mass index <30 kg/m 2 (9.4 versus 7.4 events per 100 person‐years). There was no association of dosing with mortality (HR, 0.99 [95% CI, 0.96–1.06]) or thrombotic events (HR, 1.16 [95% CI, 0.96–1.41]). Conclusions: In this nationwide study of nursing home residents with nonvalvular atrial fibrillation, we found a higher rate of bleeding and little difference in effectiveness of standard versus reduced‐dose DOAC treatment. Our results support the use of reduced‐dose DOACs for many older adults with multiple morbidities.

10 August 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
KHKaleen N. Hayes
Kaleen N. Hayes
DHDaniel A. Harris
Daniel A. Harris
AZAndrew R. Zullo
Andrew R. Zullo
PCPreeti Chachlani
Preeti Chachlani
KWKatherine J. Wen
Katherine J. Wen
VMVincent Mor
Vincent Mor
Introduction: COVID-19 booster vaccines are highly effective at reducing severe illness and death from COVID-19. Research is needed to identify whether racial and ethnic disparities observed for the primary series of the COVID-19 vaccines persist for booster vaccinations and how those disparities may vary by other characteristics. We aimed to measure racial and ethnic differences in booster vaccine receipt among U.S. Medicare beneficiaries and characterize potential variation by demographic characteristics.Methods: We conducted a cohort study using CVS Health and Walgreens pharmacy data linked to Medicare claims. We included community-dwelling Medicare beneficiaries aged ≥66 years who received two mRNA vaccine doses (BNT162b2 and mRNA-1273) as of 8/1/2021. We followed beneficiaries from 8/1/2021 until booster vaccine receipt, death, Medicare disenrollment, or end of follow-up (12/31/2021). Adjusted Poisson regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) comparing vaccine uptake between groups.Results: We identified 11,339,103 eligible beneficiaries (mean age 76 years, 60% female, 78% White). Overall, 67% received a booster vaccine (White = 68.5%; Asian = 67.0%; Black = 57.0%; Hispanic = 53.3%). Compared to White individuals, Black (RR = 0.78 [95%CI = 0.78–0.78]) and Hispanic individuals (RR = 0.72 [95% = CI 0.72–0.72]) had lower rates of booster vaccination. Disparities varied by geographic region, urbanicity, and Medicare plan/Medicaid eligibility. The relative magnitude of disparities was lesser in areas where vaccine uptake was lower in White individuals.Discussion: Racial and ethnic disparities in COVID-19 vaccination have persisted for booster vaccines. These findings highlight that interventions to improve vaccine uptake should be designed at the intersection of race and ethnicity and geographic location.